DavidMPariserMD

PubMed

• Secukinumab in patients with moderate to severe hidradenitis suppurativa based on prior biologic exposure: An efficacy and safety analysis from the SUNSHINE and SUNRIS...
  Christos C Zouboulis, Thierry Passeron, David Pariser, Magdalena B Wozniak, Xianjun Li, Lorenz Uhlmann, Iryna Lobach, Angela Llobet Martinez, Shoba Ravichandran, Ivett...> ;The British Journal of Dermatology. 2024 Mar 12
• Treatment Satisfaction and Acceptability of 20% Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses of the Face, Scalp, and Upper Extremities.
  Brocato, J., Squittieri, N., Piacquadio, D., Berman, B., Siegel, D., Bhatia, N., Pariser, D.> ;The Journal of Clinical and Aesthetic Dermatology. 2023 Dec 1
• Building a Group Practice and Going Big.
  David M Pariser> ;Dermatologic Clinics. 2023 Oct 1
• Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
  Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani, Zoe D Draelos, Janet DuBois, Melinda J Gooderham, Steven E Kempers, Edward Lain, ...> ;The British Journal of Dermatology. 2023 Sep 15
• 2 citations
  Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
  Matthew J Zirwas, Zoe D Draelos, Janet DuBois, Leon H Kircik, Angela Y Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, ...> ;JAMA Dermatology. 2023 Jun 1
• 3 citations
  Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized contr...
  Zoe D Draelos, David N Adam, H Chih-Ho Hong, Mark G Lebwohl, Charles W Lynde, Walter K Nahm, Kim A Papp, David M Pariser, Linda Stein Gold, Daniel Stewart, Robert C Hi...> ;The British Journal of Dermatology. 2023 May 24
• 7 citations
  Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled tri...
  Diamant Thaçi, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B Kimball> ;The British Journal of Dermatology. 2023 Jan 23
• 2 citations
  Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.
  Andrew Blauvelt, David M Pariser, Stephen Tyring, Jerry Bagel, Andrew F Alexis, Jennifer Soung, April W Armstrong, Elisa Muscianisi, Farid Kianifard, Jennifer Steadman...> ;Journal of Dermatological Science. 2023 Jan 1
• The Future of Contract Research Organizations in Dermatology and Aesthetic Research.
  Mark Nestor, David Pariser, James Del Rosso, Dee Anna Glaser, David Goldberg, Glynis Ablon, Z Paul Lorenc, Julie Santos> ;The Journal of Clinical and Aesthetic Dermatology. 2022 Dec 1
• 2 citations
  Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
  Linda Stein Gold, Javier Alonso-Llamazares, Zoe D Draelos, Melinda J Gooderham, Steven E Kempers, Leon H Kircik, Mark G Lebwohl, Kim A Papp, David M Pariser, Darryl P ...> ;American Journal of Clinical Dermatology. 2023 Mar 1
• 29 citations
  Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
  Mark G Lebwohl, Leon H Kircik, Angela Y Moore, Linda Stein Gold, Zoe D Draelos, Melinda J Gooderham, Kim A Papp, Jerry Bagel, Neal Bhatia, James Q Del Rosso, Laura K F...> ;JAMA. 2022 Sep 20
• The Future of Contract Research Organizations in Dermatology and Aesthetic Research.
  Mark Nestor, David Pariser, James Del Rosso, Dee Anna Glaser, David Goldberg, Glynis Ablon, Z Paul Lorenc, Julie Santos> ;The Journal of Clinical and Aesthetic Dermatology. 2022 Sep 1
• 15 citations
  Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
  Ellen J Kim, Aaron R Mangold, Jennifer A DeSimone, Henry K Wong, Lucia Seminario-Vidal, Joan Guitart, James Appel, Larisa Geskin, Edward Lain, Neil J Korman, Nathalie ...> ;JAMA Dermatology. 2022 Sep 1
• 1 citations
  Evidence Threshold for a Precision Medicine Test that Predicts Optimal Response to a Biologic Agent in Patients With Psoriasis: A Consensus Panel.
  Bruce Strober, John Fox, Eliot Jekowsky, David Pariser, Ken Schaecher> ;Journal of Drugs in Dermatology. 2022 Jun 1
• 4 citations
  Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).
  Jerry Bagel, Tien Q Nguyen, Hermenio Lima, Neal Jain, David M Pariser, Sylvia Hsu, Gil Yosipovitch, Haixin Zhang, Jingdong Chao, Shikha Bansal, Zhen Chen, Daniel Richm...> ;Dermatology and Therapy. 2022 Jun 1
• Open-Label Cohort Study to Evaluate Efficacy and Safety of Application of Glycopyrronium Cloth, 2.4% for Palmar Hyperhidrosis.
  David Pariser, Erin Rivera, Danielle Benedict> ;Journal of Drugs in Dermatology. 2022 May 1
• Approaches to Field Therapy for Actinic Keratoses: Relating Clinical Trial Results to Real-world Practice-A Commentary.
  David M Pariser> ;The Journal of Clinical and Aesthetic Dermatology. 2022 Apr 1
• Pioneers in Dermatology and Venereology: an Interview with Professor David M. Pariser.
  D M Pariser> ;Journal of the European Academy of Dermatology and Venereology. 2022 Apr 1
• 12 citations
  Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study...
  Linda Stein Gold, Hilary Baldwin, Leon H Kircik, Jonathan S. Weiss, David M. Pariser, Valerie D. Callender, Edward Lain, Michael A. Gold, Kenneth Beer, Zoe Diana Drael...> ;American Journal of Clinical Dermatology. 2021 Oct 21
• 6 citations
  Photodynamic Therapy with 5-aminolevulinic Acid 10% Gel and Red Light for the Treatment of Actinic Keratosis, Nonmelanoma Skin Cancers, and Acne: Current Evidence and ...
  Nathalie C Zeitouni, Neal Bhatia, Roger I Ceilley, Joel L Cohen, James Q Del Rosso, Angela Y Moore, Gilly Munavalli, David M Pariser, Todd Schlesinger, Daniel M Siegel...> ;The Journal of Clinical and Aesthetic Dermatology. 2021 Oct 1
• 17 citations
  Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled t...
  Linda Stein Gold, Kim A. Papp, David M. Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, M. Chen, Maria Paris, Yao Wang, Kristina...> ;Journal of the American Academy of Dermatology. 2021 Jul 31
• 2 citations
  A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm
  Bruce Strober, David M. Pariser, Ann Deren-Lewis, Tobin J. Dickerson, Mark Lebwohl, Alan Menter> ;Dermatology and Therapy. 2021 Jul 18
• 4 citations
  The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
  Kim A. Papp, Mark Lebwohl, Leon H Kircik, David M. Pariser, Bruce Strober, Gerald G. Krueger, David R. Berk, Lynn Navale, Robert C. Higham> ;Dermatology and Therapy. 2021 Jul 8
• 4 citations
  Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.
  Robert Bissonnette, Alice B. Gottlieb, Richard G. Langley, Craig L. Leonardi, Kim A. Papp, David M. Pariser, Jonathan Uy, Kim Parnell Lafferty, Wayne Langholff, Steven...> ;Drug Safety. 2021 Jun 2
• 6 citations
  Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
  Steven R. Feldman, Joseph F. Merola, David M. Pariser, Jingchuan Zhang, Yang Zhao, Alan M. Mendelsohn, Alice B. Gottlieb> ;The Journal of Dermatological Treatment. 2021 Mar 18
• Join now to see all

Journal Articles

• The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results fr...  
  Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S,�Pariser�D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Gu..., Br J Dermatol, 1/28/2019
• Continued treatment with secukinumab is associated with high retention or regain of response  
  Augustin M, Thaci D, Eyerich K, Pinter A, Radtke M, Lauffer F, Mrowietz U, Gerdes S,�Pariser�D, Lebwohl M, Sieder C, Melzer N, Reich K, Br J Dermatol, 1/10/2019
• Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice  
  Lebwohl M, Alexis AF, Beck LA, Block JK, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, Boguniewicz M, J Drugs Dermatol, 1/1/2019
• Glycopyrronium Tosylate in Pediatric Primary Axillary Hyperhidrosis: Post Hoc Analysis of Efficacy and Safety Findings by Age from Two Phase Three Randomized Controlle...  
  Douglass W Forsha, David M Pariser, Adelaide A Hebert, Dee Anna Glaser, William P Werschler, Pediatric Dermatology
• Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of two Phase 3 randomized controlled...  
  Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T, J Am Acad Dermatol, 1/31/2018
• Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Contro...  
  Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA, Am J Clin Dermatol, 1/30/2018
• Long-term safety results from a Phase 3 open-label study of a fixed combination halobetasol propionate 001% and tazarotene 0045% (HP/TAZ) lotion in moderate-to-severe ...  
  Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R, J Am Acad Dermatol, 1/15/2018
• Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)  
  Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L, Br J Dermatol, 1/10/2018
• Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials  
  Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, Drew J, Quiring J, Pariser DM, J Am Acad Dermatol, 1/9/2018
• Planimetric Post-hoc analysis of women with onychomycosis from tavborole 5% phase III studies: Evidence of greater imporvements in patients with >50% baseline infec...  
  Pariser DM, Wendelken ME, Rycerz AM, Gellings Lowe N, Montgomery Yost J, Lipner SR, J Drugs Dermatol, 1/1/2018
• Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients  
  Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisin..., BMC Cancer, 1/1/2018
• Understanding Patient Experience With Hyperhidrosis: A National Survey of 1,985 Patients  
  Glaser DA, Hebert A, Pieretti L, Pariser D, J Drugs Dermatol, 1/1/2018
• Introducing a curriculum in ethics and professionalism for dermatology residencies  
  Stoff BK, Grant-Kels JM, Brodell RT, Paller AS, Perlis CS, Mostow E, Pariser D, Bercovitch L, J Am Acad Dermatol, 1/1/2018
• Halobetasol 001%/Tazarotene 0045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy  
  Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R, J Drugs Dermatol, 1/1/2018
• Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 001%/Tazarotene 0045% Fixed Combination  
  Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R, J Drugs Dermatol, 1/1/2018
• Novel Tretinoin 005% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older  
  Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R, J Drugs Dermatol, 1/1/2018
• Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies  
  Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, Lebwohl M, J Allergy Clin Immunol Pract, 1/29/2017
• Efficacy and safety of the Janus Kinase 1 inhibitor PF-04965842 in patients with moderate to severe psoriasis: phase 2, randomized, double-blind, placebo-controlled study  
  Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, Kieras E, Parsons-Rich D, Menon S, Salganik M, Page K, Peeva E, Br J Dermatol, 1/26/2017
• Apremilast for the treatment of moderate to severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study  
  Bissonnette R, Haydey R, Rosoph L, Lynde CW, Bukhalo M, Fowler J, Delorme I, Gagn�-Henley A, Gooderham M, Poulin Y, Barber K, Jenkin P, Landells I, Pariser D, J Eur Acad Dermatol Venereol, 1/21/2017
• From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis  
  Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl ..., J Am Acad Dermatol, 1/1/2017
• Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 005% Versus Its Vehicle ...  
  Pariser DM, Bukhalo, M, Guenthner S Kempers S, Shideler S, Stein Gold L, Tschen E, Berg J, Ferdon MB, Dromgoole S, J Drugs Dermatol, 1/1/2017
• Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects ...  
  Pariser DM, Krishnaraja J, Tremblay TM, Rubison RM, Love TW, McGraw III MF, J Drugs Dermatol, 1/1/2017
• Dromgoole S Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 005% Versus ...  
  Pariser D, Bukhalo M, Guenthner S, Kempers S, Shideler S, Gold LS, Tschen E, Berg J, Ferdon MB, J Drugs Dermatol, 1/1/2017
• Greater efficacy with secukinumab treatment is associate with greater psoriasis symptom improvement relief: Resuls from secukinumab clinical trials  
  Gottlieb AB, Strober B, Lebwohl M, Kaufmann R, Pariser DM, Narbutas R, Nyirady J, Zhao Y, Herra M, McCleod L, Odom D, Elewski BE, Journal of Psoriasis and Psoriatic Arthritis, 1/1/2017
• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-...  
  Blauvelt A, de Bruin-Weller M, Gooderham M, Caher JC, Weisman J, Pariser DM, Simpson EL, Papp KA, Hong H Chin-Ho. Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Har..., Lancet, 1/1/2017
• Join now to see all

Books/Book Chapters

• Botulinum Toxins in Clinical Aesthetic Practice 
  Chapter: Botulinum toxin in the management of focal hyperhidrosis 
  Pariser DM, Glaser DAEditors: Benedetto A.CRC Press, Taylor and Francis Group, Boca Raton, FLEdition 3rd,2018
• Manual of Obstetrics 
  Chapter: Dermatologic Complications of Pregnancy 
  Pariser DM, Huntley AC, Horney DAEditors: Evans AT and Niswander KR.Lippincott-Raven and Wilkins, Philadelphia, PAEdition 6th,2000
• Care Management of Skin Diseases, Life Quality and Economic Impact 
  Chapter: Strategies for primary care physicians to manage contact dermatitis 
  Pariser DMEditors: Rajagopalan R, Sheretz EF, Adams RT.Marcel Dekker, Inc., New York, NY1998
• Saunders Manual of Medical Practice 
  Pariser DM. HyperhidrosisEditors: Rakel RE.W. B. Saunders Company, Philadelphia, PA1996
• Tecniche Per La Diagnosi Di Malattie Cutanee E Del Capelli 
  Pariser DM, Caserio RJ, Eaglstein WHMicarelli Editore, Rome, Italy1995
• Techniques for Diagnosing Skin and Hair Diseases 
  Pariser DM, Caserio RJ and Eaglstein WHThieme-Stratton, New York, NY1986
• Office Techniques for Diagnosing Skin Diseases 
  Eaglstein WH and Pariser DMYear Book Medical Publishers1978
• Join now to see all

Abstracts/Posters

• Don�t Sweat it: New Drugs for Hyperhidrosis
  Pariser DM, DermFOOT CME Conference, Tysns Corner, VA, 1/13/2019
• Biologics 101: The evolution of biologics
  Pariser DM, DermFOOT CME Conference, Tysns Corner, VA, 1/13/2019
• Scratching the surface: Psoriasis management
  Pariser DM, DermFOOT CME Conference, Tysns Corner, VA, 1/13/2019
• Innovations in hyperhidrosis
  Pariser DM, South Beach Symposium, Miami Beach, FL, 1/9/2019
• Combination therapy in managing psoriasis
  Pariser DM, South Beach Symposium, Miami Beach, FL, 1/9/2019
• Patient cases- psoriasis
  Pariser DM, South Beach Symposium, Miami Beach, FL, 1/9/2019
• Focus Session Director, Updsate on treatment of hyperhidrosis
  Pariser DM, American Academy of Dermatology Annual Meeting, Washington, DC, 1/4/2019
• Efficacy responses with tildrakizumab in moderate-to-severe chronic plaque psoriasis patients with prior exposure to apremilast: results of a pooled analysis of reSURF...
  Gordon K, Reich K, Pariser DM, Menter A, Tyring S,Sofen H, Rozzo S, Parno J, Li Q, La Rosa C, World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden, 1/30/2018
• Efficacy of Tildrakizumab in Moderate to Severe Psoriasis Patients With Prior Exposure to Apremilast
  Gordon KB, Reich K, Pariser DM, Menter A, Tyring SK, Sofen H, Rozzo SJ, Parno J, Li Q, La Rosa C, 5th World Psoriasis and Psoriatic Arthritis Conference, Internal Federation of Psorisis Associations, Stockholm, Sweeden, 1/30/2018
• New and Emerging Therapies
  Pariser DM, Amercan Academy of Dermatology, Chicago, IL, 1/27/2018
• Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMh...
  K.A. Papp, M. Gooderham, R.G. Langley, C. Leonardi, J.-P. Lacour, S. Philipp, S. Tyring, M. Bukhalo, J.J. Wu, J. Bagel, E.H. Frankel, D. Pariser, M. Flack, J. Scherer,..., Societa Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sessualmente Trasmesse, Verona, Italy, 1/26/2018
• Dupilumab and Concomitant Topical Corticosteroids in the Long-term Management of Moderate-to-Severe Atopic Dermatitis: Analysis of Clinical Outcomes by Race (LIBERTY A...
  Pariser DM, Lockshin BN, Griffiths CEM, Maui Derm NP+PA Summer, Colorado Springs, CO, 1/23/2018
• Clinical and Therapeutic Pearls in medical Dermatology
  Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
• Oral psoriasis therapy data and pearls
  Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
• Hyperhidrosis update
  Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
• Efficacy and safety of IL-23 therapies
  Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
• Managing the challenging hyperhidrosis patient
  Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
• Coding and reimbursement update
  Pariser DM, 16th Aniversary Winter Clinical Dermatology Conference, Koloa, HI, 1/23/2018
• Expert Perspectives on the Management of Moderate-to-Severe Atopic Dermatitis: Addressing Current and Emerging Therapies
  Boguniewicz M, Alexis AF, Beck LA, Block J. Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser DM, Silverberg JI,,1 Lebwohl M, Real World Dermatology for PAs and NPs, Orlando, FL, 1/22/2018
• A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid�Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities
  Jiang SB, Kempers SE, Rich PA, Marcus SL,Piacquadio DJ, Pariser DM, DERM NP and PA Conference, Las Vegas, NV, 1/22/2018
• Improving your patient interactions: Dealing with the difficult patient
  Pariser DM, Real world dermatology for PA�s and NP�s, Orlando, FL, 1/22/2018
• Evaluating and managing seborrheic keratosis and other benign lesions
  Pariser DM, Real world dermatology for PA�s and NP�s, Orlando, FL, 1/22/2018
• Long-term safety of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis
  Lebwohl MG, Sugarman JL, Stein Gold L, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R, Fall Clinical Dermatology Conference, Las Vegas, NV, 1/21/2018
• Halobetasol 0.01%/Tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: maintenance of therapeutic effect after cessation of therapy
  Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R, Ph, Fall Clinical Dermatology Conference, Las Vegas, NV, 1/21/2018
• New Options for Photodymanic Therapy
  Pariser DM, Department of Dermatology, Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University, Medical College of Virginia, New York, NY, 2017; Richmond, VA, 2018, 1/21/2018
• Join now to see all

Lectures

• Hyperhidrosis: Update on Therapeutics 
  American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019
• International Hyperhidrosis Society Hyperhidrosis Treatment and Practice Excellence 
  American Academy of Dermatology, Hoboken, New Jersey - 9/8/2012
• Managed Care and Dermatology 
  Cleveland, OH, 1994; Boston, MA, 1995 - 1/29/1995
• Managed and Capitated Care - Advantages and Disadvantages 
  San Francisco, CA - 1/31/1994
• Managed Care - Gatekeepers and Capitation 
  San Francisco, CA - 1/30/1994
• Managed Care and Managed Competition: Negotiating a Contract in Which Plans to Participate 
  Houston, TX - 1/24/1994
• Managed Care and Managed Competition: Negotiating a Contract and In Which Plans to Participate 
  Houston, TX - 1/24/1994
• Ethical Dilemmas of Managed Care 
  Philadelphia, PA - 1/22/1994
• Management of Cutaneous Fungal Infections 
  Williamsburg, VA, 1994; Hershey, PA, 1994 - 1/19/1994
• Diagnosis and Overview of Onychomycosis 
  Hershey, PA - 1/19/1994
• Treatment of Onychomycosis I - Conventional and Traditional Methods 
  Hershey, PA - 1/19/1994
• Treatment of Onychomycosis II - New Therapies 
  Hershey, PA - 1/19/1994
• Uncomplicated Cutaneous Candidiasis 
  Hershey, PA - 1/19/1994
• Treatment of Tinea Versicolor 
  Hershey, PA - 1/19/1994
• How to Approach a Nail - Anatomy 
  Hershey, PA - 1/18/1994
• Relationship of Primary Care Physicians and Dermatologists in Managed Care 
  Williamsburg, VA - 1/14/1994
• Diagnosis and treatment of cutaneous Candida, Seborrheic Dermatitis and Tinea Versicolor 
  Williamsburg, VA - 1/14/1994
• How to Manage Managed Care 
  Dana Point, CA - 1/13/1994
• Dermatology and Capitation 
  White Plains, NY, 1993; Laguna Niguel, CA, 1994 - 1/12/1994
• Clinical Manifestations of Fungal Infections 
  Flint, MI - 1/3/1994
• Diagnosis and management of Skin Fungus Infections for the Primary Care Physician 
  Allentown, PA - 1/2/1994
• Effects of Finasteride on Dihydrotestosterone Content of Scalp Skin in Men with Male Pattern Baldness 
  1/1/1994
• Diagnosis and Management of Dermatophyte Infection 
  Alpena, MI - 1/1/1994
• How Managed Care Will Affect Your Practice 
  San Francisco, CA - 1/1/1994
• Topical Steroids in Mild to Severe Dermatoses 
  Myrtle Beach, SC - 1/29/1993
• Join now to see all

Other

• Primary focal hyperhidrosis 
  Pariser D, Smith CC
  http://www.uptodate.com/contents/primary-focal-hyperhidrosis
  UpToDate, Wolters Kluwer Health - 2012-08-14